Onconova Therapeutics Inc (ONTX) Stock
ONTX is no longer traded. Onconova Therapeutics was delisted from the Nasdaq in April 2024.
Prices on this page are historical; the last trade was April 2, 2024 at $1.00.
Onconova Therapeutics stock price history
ONTX final trading statistics
- Final close
- $1.00
- Final trading day
- Apr 2, 2024
- Market cap at delisting
- $20.90M
- Shares outstanding
- 21.00M
- Final 52-week range
- $0.55 – $1.45
- Avg. volume (final 3 mo.)
- 96,273
- All-time high (split-adj.)
- $66150.00 · Aug 2013
- All-time low (split-adj.)
- $0.62 · Oct 2023
- Return since IPO
- -100.0%
- Beta
- 1.35
- Book value / share
- $0.69
- Price / book
- 1.44
Onconova Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $226.0K | -$18.9M | -$0.91 |
| FY2022 | $226.0K | -$18.3M | -$0.91 |
| FY2021 | $226.0K | -$15.8M | -$0.94 |
| FY2020 | $231.0K | -$25.2M | -$1.95 |
| FY2019 | $2.18M | -$21.5M | -$45.59 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Onconova Therapeutics Inc
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Onconova Therapeutics stock FAQ
What happened to Onconova Therapeutics stock?
Onconova Therapeutics stock was delisted from the Nasdaq. Its final close was $1.00 on April 2, 2024.
Is ONTX stock still trading?
No. ONTX was delisted from the Nasdaq in April 2024 and no longer trades on a U.S. exchange.
What was the last price of ONTX stock?
ONTX closed at $1.00 on its final trading day, April 2, 2024, for a market value of about $20.90M.
What were Onconova Therapeutics's revenue and earnings in its last full fiscal year?
Onconova Therapeutics reported revenue of $226.0K and net income of -$18.9M in fiscal 2023, its last full year as a public company.
When did Onconova Therapeutics go public?
Onconova Therapeutics Inc stock began trading on July 25, 2013.